Lin W, Zhang J, Liu X, Liu H, He J, Li M, Zhang S, Zhang Y, Chen H, Zhang C, Wu W, Jin C, Lee SS, Duan Z

Idioma: Ingles.
Referencias bibliográficas: 35
Paginas: 392-402
Archivo PDF: 186.22 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-37.

2. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009; 3: 269-82.

3. Galbois A, Das V, Carbonell N, Guidet B. Prognostic scores for cirrhotic patients admitted to an intensive care unit: which consequences for liver transplantation? Clin Res Hepatol Gastroenterol 2013; 37: 455-66.

4. Wan Z, Wu Y, Yi J, You S, Liu H, Sun Z, Zhu B, et al.Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure. PLoS One 2015; 28: e0116968.

5. Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta- analysis. PloS one 2013; 8: e54773.

6. Zhang L, Hao CQ, Liu JF, Wang M. Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B. Virol J 2013; 10: 134.

7. Zhang L, Hao CQ, Liu JF, Wang M. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta -analysis. Ann Hepatol 2013; 12: 364-72.

8. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.

9. Runyon BA; AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013; 57: 1651-3.

10. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy- Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.

11. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

12. Kanno A, Suzuki H, Miyazaki Y, Sato S, Otsuki M, Goto Y, Ohori H. Severe acute exacerbation in chronic hepatitis B virus infection in Sendai, Japan. Tohoku J Exp Med 1988; 155: 363-71.

13. Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, et al. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol 2014; 60: 1127-34.

14. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-onchronic liver failure. Hepatology 2011; 53: 774-80.

15. Garg V1, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhuja P, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 505-12.

16. Garg H, Kumar A, Garg V, Sharma P, Sharma BC, Sarin SK. Clinical profile and predictors of mortality in patients of acute-on-chronic liver failure. Dig Liver Dis 2012; 44: 166- 71.

17. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med 2012; 12(3): 159-64.

18. Ma K, Guo W, Han M, Chen G, Chen T, Wu Z. Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure: Establishment of a novel logistical regression model. Hepatol Int 2012;6(4):735-43.

19. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-onchronic hepatitis B liver failure. J Gastroenterol Hepatol 2010; 25(3): 583-90.

20. Zhang X, An Y, Jiang X, Xu M, Xu L, Chen S, Xi Y. Entecavir Versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis. Hepat Mon 2014; 14: e19164.

21. Pan CQ, Zhang JX. Natural history and clinical consequences of hepatitis B Virus infection. Int J Med Sci 2005; 2: 36-40.

22. Xu Z, Ren X, Liu Y, Li X, Bai S, Zhong Y, Wang L, et al. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure. J Gastroenterol 2011; 46: 391-400.

23. Xiao L, Zhou B, Gao H, Ma S, Yang G, Xu M, Abbott WG, et al. Hepatitis B virus genotype B with G1896A and A1762T/ G1764A mutations is associated with hepatitis B related acute-on-chronic liver failure. J Med Virol 2011; 83: 1544-50.

24. Ren X, Xu Z, Liu Y, Li X, Bai S, Ding N, Zhong Y, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat 2010; 17: 887-95.

25. Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen QQ, Chen YP. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol 2011; 9: 351-6.

26. Sun QF, Ding JG, Xu DZ, Chen YP, Hong L, Ye ZY, Zheng MH, et al. Prediction of the prognosis of patients with acuteon- chronic hepatitis B liver failure using the model for endstage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009; 16: 464-70.

27. Naiki T, Nakayama N, Mochida S, Oketani M, Takikawa Y, Suzuki K, Tada S, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: Application to indication criteria for liver transplantation. Hepatol Res 2012; 42: 68-75.

28. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM. Acute Liver Failure Study Group. Thrombocytopenia is associated with multi-organ system failure in patients with acute liver failure. Clin Gastroenterol Hepatol 2016; 14: 613-20.

29. Lee WM. Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol 2012; 26: 3-16.

30. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006; 312: 104-7.

31. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. Hepatology 2013; 58: 752-61.

32. Ha JM, Sohn W, Cho JY, Pyo JH, Choi K, Sinn DH, Gwak GY, et al. Static and dynamic prognostic factors for hepatitis-Brelated acute-on-chronic liver failure. Clin Mol Hepatol 2015; 21: 232-41.

33. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, et al. Evaluation of the increase in model for end-stage liver disease (Delta MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005; 42: 826-32.

34. Chamuleau RA, Wlodzimirow KA, Abu-Hanna A. Incorporating dynamics for predicting poor outcome in acute liver failure patients. World J Gastrointest Surg 2012; 4: 281-3.

35. Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, et al. Clinical course of acute-onchronic liver failure syndrome and effects on prognosis. Hepatology 2015; 62: 243-52.